Association between the functional polymorphism (C3435T) of the gene encoding P-glycoprotein (ABCB1) and major depressive disorder in the Japanese population

Journal of Psychiatric Research

Volumn 46, Issue 4, 2012, Pages 555-559

  Fujii, Takashi ^a   Ota, Miho ^a   Hori, Hiroaki ^a,b   Sasayama, Daimei ^a   Hattori, Kotaro ^a   Teraishi, Toshiya ^a   Yamamoto, Noriko ^a   Hashikura, Miyako ^a   Tatsumi, Masahiko ^c   Higuchi, Teruhiko ^d   Kunugi, Hiroshi ^a,b  

^a NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c Yokohama Shinryo Clinic   (Japan)

^d NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

Author keywords

ABCB1; Functional polymorphism; Genetic association; Major depressive disorder; P glycoprotein

Indexed keywords

GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; PHOSPHODIESTERASE I;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE DOSAGE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOIDY; HAPLOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; PYROSEQUENCING; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84858278173     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2012.01.012     Document Type: Article

References (31)

1. American Psychiatric Association DSM-IV: diagnostic and statistical manual of mental disorders 1994, American Psychiatric Press, Washington D.C. 4th ed.
2. Cascorbi I., Gerloff T., Johne A., Meisel C., Hoffmeyer S., Schwab M., et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clinical Pharmacology andamp; Therapeutics 2001, 69:169-174.
3. Chen C.J., Chin J.E., Ueda K., Clark D.P., Pastan I., Gottesman M.M., et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986, 47:381-389.
4. Ejsing T.B., Hasselstrom J., Linnet K. The influence of P-glycoprotein on cerebral and hepatic concentrations of nortriptyline and its metabolites. Drug Metabolism and Drug Interactions 2006, 21:139-162.
5. Gex-Fabry M., Eap C.B., Oneda B., Gervasoni N., Aubry J.M., Bondolfi G., et al. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. Therapeutic Drug Monitoring 2008, 30:474-482.
6. Goto M., Masuda S., Saito H., Uemoto S., Kiuchi T., Tanaka K., et al. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics 2002, 12:451-457.
7. Grauer M.T., Uhr M. P-glycoprotein reduces the ability of amitriptyline metabolites to cross the blood brain barrier in mice after a 10-day administration of amitriptyline. Journal of Psychopharmacology 2004, 18:66-74.
8. Hoffmeyer S., Burk O., von Richter O., Arnold H.P., Brockmoller J., Johne A., et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proceedings of the National Academy of Sciences USA 2000, 97:3473-3478.
9. Kato M., Fukuda T., Serretti A., Wakeno M., Okugawa G., Ikenaga Y., et al. ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2008, 32:398-404.
10. Kimchi-Sarfaty C., Oh J.M., Kim I.W., Sauna Z.E., Calcagno A.M., Ambudkar S.V., et al. A andquot;silentandquot; polymorphism in the MDR1 gene changes substrate specificity. Science 2007, 315:525-528.
11. Kioka N., Tsubota J., Kakehi Y., Komano T., Gottesman M.M., Pastan I., et al. P-glycoprotein gene (MDR1) cDNA from human adrenal: normal P-glycoprotein carries Gly185 with an altered pattern of multidrug resistance. Biochemical and Biophysical Research Communications 1989, 162:224-231.
12. Koyama T., Nakamura T., Komoto C., Sakaeda T., Taniguchi M., Okamura N., et al. MDR1 T-129C polymorphism can be predictive of differentiation, and thereby prognosis of colorectal adenocarcinomas in Japanese. Biological andamp; Pharmaceutical Bulletin 2006, 29:1449-1453.
13. Kunugi H., Hori H., Adachi N., Numakawa T. Interface between hypothalamic-pituitary-adrenal axis and brain-derived neurotrophic factor in depression. Psychiatry and Clinical Neurosciences 2010, 64:447-459.
14. Li J., Ji L. Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity 2005, 95:221-227.
15. Menu P., Gressier F., Verstuyft C., Hardy P., Becquemont L., Corruble E. Antidepressants and ABCB1 gene C3435T functional polymorphism: a naturalistic study. Neuropsychobiology 2010, 62:193-197.
16. Mihaljevic-Peles A., Bozina N., Sagud M. Pharmacogenetics in modern psychiatry. Psychiatria Danubina 2007, 19:231-233.
17. Mihaljevic Peles A., Bozina N., Sagud M., Rojnic Kuzman M., Lovric M. MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2008, 32:1439-1444.
18. Nyholt D.R. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. American Journal of Human Genetics 2004, 74:765-769.
19. Otsubo T., Tanaka K., Koda R., Shinoda J., Sano N., Tanaka S., et al. Reliability and validity of Japanese version of the mini-international neuropsychiatric Interview. Psychiatry and Clinical Neurosciences 2005, 59:517-526.
20. Peters E.J., Slager S.L., Kraft J.B., Jenkins G.D., Reinalda M.S., McGrath P.J., et al. Pharmacokinetic genes do not influence response or tolerance to citalopram in the STARandz.ast;D sample. PLoS One 2008, 3:e1872.
21. Qian W., Homma M., Itagaki F., Tachikawa H., Kawanishi Y., Mizukami K., et al. MDR1 gene polymorphism in Japanese patients with schizophrenia and mood disorders including depression. Biological andamp; Pharmaceutical Bulletin 2006, 29:2446-2450.
22. Roberts R.L., Joyce P.R., Mulder R.T., Begg E.J., Kennedy M.A. A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics Journal 2002, 2:191-196.
23. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry 1998, 59(Suppl. 20):22-33. quiz 34-57.
24. Tanabe M., Ieiri I., Nagata N., Inoue K., Ito S., Kanamori Y., et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. Journal of Pharmacology and Experimental Therapeutics 2001, 297:1137-1143.
25. Uhr M., Grauer M.T., Holsboer F. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biological Psychiatry 2003, 54:840-846.
26. Uhr M., Grauer M.T., Yassouridis A., Ebinger M. Blood-brain barrier penetration and pharmacokinetics of amitriptyline and its metabolites in p-glycoprotein (abcb1ab) knock-out mice and controls. J Psychiatry Research 2007, 41:179-188.
27. Uhr M., Steckler T., Yassouridis A., Holsboer F. Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology 2000, 22:380-387.
28. Uhr M., Tontsch A., Namendorf C., Ripke S., Lucae S., Ising M., et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 2008, 57:203-209.
29. Wang D., Johnson A.D., Papp A.C., Kroetz D.L., Sadee W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435Cgt;T affects mRNA stability. Pharmacogenet Genomics 2005, 15:693-704.
30. Wang J.S., Zhu H.J., Gibson B.B., Markowitz J.S., Donovan J.L., DeVane C.L. Sertraline and its metabolite desmethylsertraline, but not bupropion or its three major metabolites, have high affinity for P-glycoprotein. Biological andamp; Pharmaceutical Bulletin 2008, 31:231-234.
31. Wong M., Evans S., Rivory L.P., Hoskins J.M., Mann G.J., Farlow D., et al. Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer. Clinical Pharmacology andamp; Therapeutics 2005, 77:33-42.